Eloralintide and Amycretin: Next-Generation Amylin and GLP-1 Agonists for Obesity

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to eloralintide or amycretin. Neither compound is FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The obesity drug pipeline has been dominated by GLP-1 for a decade. Semaglutide and tirzepatide have reset expectations for what weight loss pharmacotherapy can achieve. But a parallel conversation is taking place in metabolic research, and it centers on a hormone most people have never heard of: amylin.

Amylin is secreted alongside insulin from the pancreatic beta cells. It tells the brain that food has arrived, slows gastric emptying, and suppresses glucagon. In individuals with type 2 diabetes and obesity, amylin signaling is blunted or absent. The question researchers began asking was whether restoring that signal, alone or in combination with GLP-1 activity, could produce weight loss that exceeds what either pathway delivers on its own.

Two compounds are at the center of that question: eloralintide, a long-acting amylin receptor agonist developed by Eli Lilly, and amycretin, a first-in-class dual GLP-1/amylin receptor agonist developed by Novo Nordisk. This article covers what both compounds are, how the amylin mechanism works, what the clinical data shows so far, and where each compound stands in the regulatory process as of April 2026.

Key Takeaways

• Regulatory Status: Neither compound is FDA-approved as of April 2026. Eloralintide (LY3841136) has completed Phase 2; amycretin has completed Phase 1 (oral and subcutaneous formulations) with Phase 2 ongoing. Neither has an approved NDA. Superpower does not offer either compound.
• Research Stage: Eloralintide: Phase 2 completed (48-week double-blind multicenter RCT published in Lancet, 2025). Amycretin: Phase 1 completed for both oral and subcutaneous formulations; subcutaneous Phase 1b/2a showed approximately 13% weight loss in 12 weeks. Phase 3 design is underway for both programs as of April 2026.
• Availability: Not available for human use in the United States. Superpower does not offer these substances. For ongoing trial information, see clinicaltrials.gov.
• What they are: Eloralintide is a once-weekly injectable selective amylin receptor agonist; amycretin is a first-in-class injectable (and oral formulation in development) dual GLP-1 and amylin receptor co-agonist.
• What the evidence actually shows: Phase 1/2 data in humans demonstrates clinically meaningful weight loss for both compounds; Phase 3 data has not been published as of April 2026, and long-term safety data in large populations does not yet exist.

The Amylin Class: Why Researchers Are Looking Beyond GLP-1

What amylin is and what it does

Amylin (islet amyloid polypeptide, or IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. Its physiological roles have been catalogued in detail since the early 2000s. A comprehensive 2015 pharmacology review by Hay, Chen, Lutz, Parkes, and Roth, published in Pharmacological Reviews, established that amylin acts centrally in the area postrema and hypothalamus to reduce food intake, inhibit glucagon secretion, and slow gastric emptying in a manner that complements but is mechanistically distinct from GLP-1. The foundational biology of native amylin was described by Westermark, Andersson, and Westermark in a 2011 review in Physiological Reviews, which established IAPP's role in beta cell signaling and its pathological aggregation in type 2 diabetes. A 2022 review by Boyle, Zheng, and Lutz in Journal of Clinical Medicine clarified the mediators of amylin action in metabolic control, particularly its interaction with calcitonin gene-related peptide receptors (CTR/RAMP) in the brainstem and hypothalamus. Lutz, writing in Neuropharmacology in 2025, provided a focused account of how amylin drives feeding suppression and satiation at the circuit level — the neural substrate behind the clinical weight loss effects observed in trials. Eržen, Tonin, and colleagues, writing in the International Journal of Molecular Sciences in 2024, positioned amylin as another important neuroendocrine hormone for the treatment of what they termed "diabesity" — the overlap between type 2 diabetes and obesity. Most recently, a 2025 review by Walker and Aitken in Nature Reviews Endocrinology documented amylin's emergent therapeutic opportunities in overweight, obesity, and diabetes, positioning the class as a distinct complement to GLP-1 pharmacotherapy.

The problem with native amylin and pramlintide

Native amylin has two pharmacological limitations that prevented it from becoming a clinical obesity treatment: it self-aggregates into amyloid fibrils and has a short half-life that requires multiple daily injections. Pramlintide, a synthetic amylin analog approved by the FDA for type 2 and type 1 diabetes (as Symlin), partially solved the aggregation problem by substituting three residues, but retained the requirement for injection with every meal. A Phase 2 study of pramlintide in obese subjects without diabetes, published in 2007 in Journal of Clinical Endocrinology and Metabolism by Aronne, Fujioka, Aroda, and colleagues, demonstrated dose-dependent weight reduction of approximately 3% to 5% in 16 weeks, establishing proof of concept for amylin-class pharmacotherapy in obesity but also illustrating the ceiling imposed by pramlintide's short duration of action. The next generation of amylin analogs, including cagrilintide, eloralintide, and the amylin component of amycretin, was engineered to achieve once-weekly (or less frequent) dosing and to avoid aggregation entirely.

Why dual agonism with amylin may exceed GLP-1 monotherapy

The rationale for combining amylin signaling with GLP-1 activity is mechanistic complementarity. GLP-1 receptor agonists act primarily through vagal afferents and hypothalamic nuclei to reduce appetite and slow gastric motility. Amylin acts through the area postrema (a circumventricular organ outside the blood-brain barrier) and interacts with separate hypothalamic circuits. Stimulating both pathways simultaneously may produce additive or synergistic satiety signaling without proportionally scaling the side effect burden of either mechanism alone. A 2021 review of GLP-1 receptor co-agonists for metabolic disease by Baggio and Drucker in Molecular Metabolism established the theoretical and preclinical basis for this co-agonist rationale, and the Phase 3 CagriSema program (cagrilintide plus semaglutide) provided the first large-scale human test of the concept. A 2025 systematic review of emerging obesity pharmacotherapies by Kokkorakis and colleagues in Pharmacological Reviews provided updated pipeline context, noting that amylin-based agents are now a recognized distinct pharmacological class in the anti-obesity pipeline.

Eloralintide: What the Research Shows

Discovery and mechanism

Eloralintide (development name LY3841136) is a long-acting synthetic amylin receptor agonist developed by Eli Lilly and Company. The discovery and first-in-human study were published in 2025 in Molecular Metabolism by Briere, Qu, Lansu, and colleagues at Eli Lilly. That translational paper combined in vitro receptor assays, rodent and non-human primate models, and a Phase 1 randomized placebo-controlled trial in 48 healthy participants (36 eloralintide, 12 placebo), describing eloralintide's identification as a selective amylin analog engineered for once-weekly subcutaneous administration, its preferential binding at the human AMY1R (calcitonin receptor/receptor activity-modifying protein 1) complex, and its pharmacokinetics in first-in-human studies — with participants receiving 4 mg or 12 mg experiencing 2.5% and 4.4% body weight reductions versus a 0.6% increase on placebo over the dosing period. Eloralintide was specifically designed to bind the amylin receptor subtype expressed in the area postrema without significant activity at the calcitonin receptor, which is associated with bone-related pharmacology and may contribute to off-target effects with less selective compounds. A 2026 Phase 1 multiple-ascending-dose study in Diabetes, Obesity and Metabolism by Bhattachar, Tham, and colleagues randomized 100 adults with overweight or obesity (mean age 44, 29% female, mean BMI 32.6 kg/m²) across five once-weekly subcutaneous dose cohorts versus placebo at three U.S. centers in a participant- and investigator-blinded design; at week 12, mean body weight reduction ranged from 2.6% to 11.3% across dose groups versus placebo (p < 0.001 for active-dose comparisons), with the most common adverse events being decreased appetite (19%), headache (12%), fatigue (11%), diarrhea (10%), nausea (8%), and vomiting (4%); one serious adverse event occurred and was judged unrelated to study drug. The modest per-cohort sample size and 12-week duration limit inference about durability and rare adverse events.

Phase 2 efficacy data

The primary efficacy data for eloralintide come from a 48-week Phase 2 multicenter double-blind randomized controlled trial published in 2025 in The Lancet by Billings, Hsia, Bays, and colleagues. The trial enrolled 263 adults (78% female, mean age 49 years) with overweight or obesity without type 2 diabetes and randomized them to once-weekly subcutaneous placebo or eloralintide at 1 mg, 3 mg, 6 mg, 9 mg, or escalating regimens for 48 weeks. Mean body weight change was -0.4% on placebo versus -9% at 1 mg, -12% at 3 mg, -18% at 6 mg, and -20% at 9 mg, with escalation arms reaching -16% to -20%. Nausea (11-64% across doses versus 14% placebo) and fatigue (0-46% across doses versus 12% placebo) were the dominant adverse events, consistent with the class pharmacology of amylin-receptor activation. Because Phase 3 data have not been published as of April 2026, the external generalizability of these Phase 2 findings remains to be confirmed in larger populations, and the small per-arm sample sizes limit precision of the point estimates at each dose.

What differentiates eloralintide from GLP-1 monotherapy

As a selective amylin receptor agonist, eloralintide does not directly activate GLP-1, GIP, or glucagon receptors. Its mechanism is distinct from semaglutide, tirzepatide, and the emerging triple-receptor agonist retatrutide. Tirzepatide's own evidence base — built from the SURMOUNT-1 Phase 3 trial in 2,539 adults with obesity or overweight plus a weight-related complication, reported by Jastreboff, Aronne, Ahmad, and colleagues in the New England Journal of Medicine in 2022, which showed mean body weight change of -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg versus -3.1% on placebo at 72 weeks (p < 0.001), the SURMOUNT-2 Phase 3 trial in 938 adults with obesity and type 2 diabetes published by Garvey, Frias, Jastreboff, and colleagues in The Lancet in 2023, which reported 13.4% weight loss at tirzepatide 10 mg and 15.7% at 15 mg versus 3.3% on placebo at 72 weeks, the SURMOUNT-4 maintenance-of-weight-reduction trial (n = 670) published by Aronne, Sattar, Horn, and colleagues in JAMA in 2024, which showed continued tirzepatide produced a further -5.5% weight change versus +14.0% with placebo switch over 52 weeks (p < 0.001), and the 176-week SURMOUNT-1 extension in 1,032 participants with obesity and prediabetes, published by Jastreboff, le Roux, Stefanski, and colleagues in the New England Journal of Medicine in 2025, which reported sustained weight reduction and reduced progression to type 2 diabetes — provides the clinical benchmark against which next-generation compounds are now assessed. Retatrutide, the triple GIP/GLP-1/glucagon receptor agonist, added a separate efficacy data point: Jastreboff, Kaplan, Frías, and colleagues, writing in the New England Journal of Medicine in 2023, reported in a 338-adult Phase 2 trial mean body weight change of -8.7% at 1 mg, -17.1% at 4 mg, -22.8% at 8 mg, and -24.2% at 12 mg versus -2.1% on placebo at 48 weeks, and Sanyal and colleagues in a 2024 Nature Medicine Phase 2a trial, extended retatrutide's relevance into metabolic dysfunction-associated steatotic liver disease (MASLD). This selectivity has two potential clinical implications for eloralintide. First, it can be combined with GLP-1 agonists (including semaglutide) without receptor pathway redundancy, which is the design logic behind the cagrilintide/semaglutide combination (CagriSema). Second, its side effect profile may differ from GLP-1-class compounds, particularly with respect to nausea and gastrointestinal motility, since the dominant amylin mechanism operates through central circuits rather than peripheral gut receptors. Whether this translates to a meaningfully different tolerability experience in humans will require head-to-head Phase 3 data that does not yet exist.

Amycretin: What the Research Shows

Discovery and dual-receptor mechanism

Amycretin is a first-in-class synthetic peptide designed to co-activate both the GLP-1 receptor and the amylin receptor simultaneously from a single molecule. It was developed by Novo Nordisk. Preclinical efficacy data were published in 2025 in eBioMedicine by Kuhre, Ballarín-González, and colleagues, who demonstrated dose-dependent reductions in body weight and improvements in metabolic dysfunction markers in mouse and rat models, with effects exceeding those of GLP-1 receptor agonist monotherapy at matched doses in the same preclinical models. The molecular design of amycretin co-opts the structural features of native amylin and GLP-1 into a single amino acid sequence with optimized receptor binding affinity at both targets, long plasma half-life, and reduced propensity for amyloid aggregation.

Phase 1 oral formulation data

The first-in-human Phase 1 randomized, double-blind, placebo-controlled first-in-human trial of the oral formulation of amycretin, published in 2025 in The Lancet by Gasiorek, Heydorn, Kruse, and colleagues, enrolled 144 participants across four parts: a single-ascending-dose cohort (Part A, N = 48, 1-25 mg, 50-day duration), a 10-day multiple-ascending-dose cohort (Part B, N = 36, 3-12 mg daily), and 12-week fixed-titration cohorts escalating to 50 mg or 100 mg daily (Parts C/D, N = 60, 19-week total duration). The pharmacokinetic primary endpoints demonstrated dose-proportional plasma exposure (AUC and Cmax), with body weight change tracked as an exploratory pharmacodynamic endpoint at day 85. Treatment-emergent adverse events were reported in 89 of 144 participants (62%, 364 events total), predominantly gastrointestinal (49% of events), all mild-to-moderate in severity, with dose-dependent frequency — consistent with the known pharmacology of GLP-1 receptor agonism at equivalent exposures. Oral GLP-1 formulations have historically faced substantial bioavailability challenges; these Phase 1 data establish the oral formulation as viable for further clinical development, though the short durations and modest per-cohort sample sizes preclude conclusions about durable weight loss or rare adverse events. Oral GLP-1 formulations have historically faced substantial bioavailability challenges; the Phase 1 data represent a significant proof-of-concept for the oral GLP-1/amylin approach. The predominant adverse events were gastrointestinal and consistent with the known pharmacology of GLP-1 receptor agonism at equivalent exposure levels.

Phase 1b/2a subcutaneous data and the landmark weight loss result

The most consequential data for amycretin come from a Phase 1b/2a randomized, placebo-controlled multipart study of the subcutaneous formulation published in 2025 in The Lancet by Dahl, Toubro, Dey, and colleagues, which enrolled 125 adults (101 amycretin, 24 placebo; ages 18-55, BMI 27.0-39.9) across single- and multiple-ascending-dose parts. In the 36-week multiple-ascending-dose parts, body weight change at week 36 was -24.3% on amycretin 60 mg versus -1.1% on placebo (Part B) and -22.0% on 20 mg versus +1.9% on placebo (Part C), with statistical significance of p < 0.0001 for the primary comparisons across Parts A-D and p = 0.0003 for Part E. The predominantly gastrointestinal adverse-event profile was consistent with GLP-1 pharmacology at equivalent exposures. For context, the STEP 1 Phase 3 trial of once-weekly semaglutide 2.4 mg in 1,961 adults with overweight or obesity, published in 2021 in The New England Journal of Medicine by Wilding, Batterham, Calanna, and colleagues, demonstrated mean weight loss of -14.9% versus -2.4% with placebo over 68 weeks (p < 0.001). Cross-trial comparison is not valid given different durations, populations, and designs, so amycretin's Part B result cannot be directly equated with STEP 1, and Phase 3 data with longer follow-up and larger populations are required before durability and safety can be fully characterized.

The Amylin Class in Context: Cagrilintide and CagriSema

Cagrilintide as the class predecessor

Eloralintide and amycretin sit within a broader amylin-class development program. The most clinically advanced amylin analog as of April 2026 is cagrilintide (Novo Nordisk), a long-acting amylin analog in Phase 3. A once-weekly dose-finding Phase 2 trial of cagrilintide monotherapy in 706 adults with overweight or obesity (plus 99 liraglutide and 101 placebo controls), published in 2021 in The Lancet by Lau, Erichsen, Francisco, and colleagues, established dose-dependent weight loss — 6.0% to 10.8% across the 0.3-4.5 mg cagrilintide doses versus 3.0% on placebo and 9.0% on liraglutide 3.0 mg — that formed the basis for the CagriSema combination program. A Phase 2 CagriSema trial in 92 adults with type 2 diabetes, published in 2023 in The Lancet by Frias, Deenadayalan, Erichsen, and colleagues, showed that coadministration of cagrilintide 2.4 mg with semaglutide 2.4 mg produced mean body-weight change of -15.6% at 32 weeks versus -5.1% with semaglutide alone and -8.1% with cagrilintide alone, exceeding what either compound produced as monotherapy in this head-to-head design; the small cohort limits precision. The Phase 3 REDEFINE program then extended this to larger populations. REDEFINE 1, published in 2025 in The New England Journal of Medicine by Garvey, Blüher, Osorto Contreras, and colleagues, and REDEFINE 2, published simultaneously by Davies, Bajaj, Broholm, and colleagues, represent the landmark Phase 3 confirmation of the CagriSema combination in adults with overweight or obesity and — in REDEFINE 2 — in adults with overweight, obesity, and type 2 diabetes. These Phase 3 data provide the clearest view to date of what amylin/GLP-1 co-stimulation can achieve at scale, and they frame the clinical context into which eloralintide and amycretin are entering.

Where eloralintide and amycretin fit relative to existing compounds

Eloralintide is positioned as a standalone amylin receptor agonist that could be used as monotherapy or combined with GLP-1 agonists as separate agents, analogous to the cagrilintide-plus-semaglutide approach but with a potentially more selective amylin receptor binding profile. Amycretin occupies a different position: it delivers both GLP-1 and amylin activity from a single molecule, eliminating the need for combination therapy and — if the oral formulation succeeds — potentially enabling a non-injectable approach to dual-mechanism metabolic control. The critical distinguishing feature is that amycretin delivers the combined mechanism in one compound, whereas cagrilintide and eloralintide are designed for use alongside separate GLP-1 agonists.

This comparison is for scientific context only. Eloralintide, amycretin, cagrilintide, semaglutide, and tirzepatide have fundamentally different regulatory statuses, evidence bases, and risk profiles. None of the unapproved compounds discussed here should be interpreted as equivalent to or interchangeable with FDA-approved medications.

Several recent pipeline reviews help place this activity in context. Drucker and Holst, writing in Nature Reviews Drug Discovery in 2025, surveyed GLP-1-based therapies across diabetes, obesity, and expanding indications, and characterized the amylin-class co-agonist strategy as one of the most credible near-term extensions of the GLP-1 paradigm. Melson, Ashraf, Papamargaritis, and Davies, publishing in the International Journal of Obesity in 2025, reviewed what the pipeline for future obesity medications actually contains — including the Novo Nordisk and Eli Lilly programs that yielded amycretin and eloralintide — and emphasized that amylin agonism has moved from peripheral interest to a core component of multiple late-stage metabolic pipelines. Camilleri and Acosta, writing in the British Journal of Pharmacology in 2024, reviewed newer pharmacological interventions directed at gut hormones for obesity and highlighted the mechanistic rationale for combining amylin and GLP-1 signaling that underpins the amycretin design.

Regulatory and Legal Status

FDA classification

As of April 2026, neither eloralintide nor amycretin is FDA-approved for any indication. Both compounds are in active clinical development; neither has been submitted for NDA review in the United States. Eloralintide has completed Phase 2 and Eli Lilly has indicated intent to advance to Phase 3. Amycretin has completed Phase 1 (both formulations) and the Phase 1b/2a subcutaneous efficacy study, with Novo Nordisk advancing the program toward Phase 3 design. Neither compound is legally marketed for human use, and neither is available through compounding pharmacies or any US commercial channel.

Sport ban status

As of the 2026 WADA Prohibited List, eloralintide and amycretin are classified under the S0 category (Non-Approved Substances), which prohibits any pharmacological substance not approved by a regulatory authority for human therapeutic use. Competitive athletes subject to WADA or USADA rules should be aware that any use of these compounds, including in clinical trials, may carry anti-doping implications.

What this means practically

Products labeled as eloralintide or amycretin sold through online or gray-market research compound vendors are not regulated by the FDA, have no verified manufacturing standards, and carry unknown contamination and dosing risks. The FDA does not authorize use of investigational compounds outside of registered clinical trials with approved protocols. There is no legal pathway to obtain pharmaceutical-grade eloralintide or amycretin for human use outside of an active enrolled clinical trial as of April 2026.

Safety: What Is and Is Not Known

What Phase 1 and Phase 2 data reveal

Published safety data for both compounds are limited to the Phase 1 and Phase 2 studies listed above, with follow-up periods of 12 to 48 weeks and sample sizes characteristic of early-phase trials. For eloralintide, the 2025 Billings Lancet publication and the 2025 Briere Molecular Metabolism study report adverse events within the framework of the published trial protocols; gastrointestinal events (nausea, vomiting, constipation) consistent with the pharmacology of appetite-suppressing compounds were among the most commonly reported findings. For amycretin, the Phase 1 Gasiorek and Dahl studies reported predominantly gastrointestinal adverse events for both formulations, with no unexpected safety signals identified at the doses studied. Neither compound has completed Phase 3 or demonstrated long-term safety data (beyond 48 weeks) in published human trials.

Absence of long-term human safety data

The known risks of both compounds in clinical practice remain incompletely characterized. Phase 1 and 2 trials are designed to assess preliminary tolerability and pharmacodynamics, not to detect rare adverse events or long-term organ effects. For amylin-class compounds specifically, long-term data on bone density (relevant given calcitonin receptor proximity in the class), renal function, and cardiovascular outcomes are not yet available for eloralintide or amycretin. These will require large Phase 3 trials and post-approval surveillance studies to characterize.

Risks from unregulated sources

Research-compound vendors selling peptides of this class online are not operating under GMP (Good Manufacturing Practice) standards. Independent testing of peptide products from such vendors has documented contamination with unintended substances, incorrect concentrations, misidentified compounds, and bacterial endotoxins. These risks apply to all research peptides and are not specific to the amylin class — but they are particularly relevant here because neither compound has a verified pharmaceutical reference product or established dose-response relationship outside of tightly controlled trial conditions.

Who Should Not Use These Compounds

Based on the proposed mechanisms of eloralintide and amycretin, the following groups face elevated theoretical risk. This list reflects mechanistic reasoning from available preclinical and early clinical data; it is not derived from completed long-term human safety studies, which do not yet exist for either compound.

• Individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 — GLP-1 receptor agonists carry a class warning for this population; amycretin's GLP-1 component makes this consideration directly applicable.
• Individuals with a history of pancreatitis — GLP-1 receptor agonism is associated with elevated pancreatitis risk in post-marketing surveillance; amycretin's GLP-1 activity raises the same theoretical concern.
• Individuals with severe renal impairment — amylin receptor activity and GLP-1 receptor activity both involve renal clearance pathways; pharmacokinetics in severe renal disease have not been fully characterized for either compound.
• Pregnant or breastfeeding individuals — no safety data exists for these populations for either compound.
• Individuals with known hypocalcemia or bone metabolism disorders — amylin analogs act on receptors in the calcitonin receptor family; potential effects on calcium homeostasis and bone turnover at clinical doses have not been characterized in long-term studies.
• Competitive athletes subject to WADA or USADA rules — both compounds are classified as non-approved substances under S0 as of the 2026 WADA Prohibited List.

Which Biomarkers Are Relevant if You Are Exploring Metabolic Health?

Whether someone is following the amylin research pipeline because of personal interest in metabolic health, weight management, or diabetes prevention, understanding their current metabolic baseline through objective testing provides context that research alone cannot. The markers below reflect the physiological systems that amylin and GLP-1 agonists act on in clinical trials, and they are the same markers that providers use to evaluate metabolic health and therapeutic candidacy.

• Fasting glucose and HbA1c: These measure current and average glycemic control, respectively. The HbA1c reflects the prior three-month average of blood glucose and is a primary outcome marker in all amylin/GLP-1 trials in patients with type 2 diabetes. Understanding these values contextualizes both the metabolic need for intervention and the baseline against which any future glycemic change would be measured.
• Fasting insulin: Amylin and GLP-1 both interact with insulin secretion and insulin sensitivity. Measuring fasting insulin alongside glucose helps characterize insulin resistance before symptoms of type 2 diabetes appear, which is typically the clinical context in which these compounds are studied.
• High-sensitivity C-reactive protein (hs-CRP): Obesity is an inflammatory state, and adipose tissue dysfunction drives systemic low-grade inflammation. GLP-1 receptor agonists have demonstrated anti-inflammatory effects in clinical trials beyond their weight loss effects. Baseline hs-CRP provides a reference point for assessing metabolic inflammation.
• Lipid panel (triglycerides, HDL, LDL, ApoB): Weight loss interventions produce characteristic changes in the lipid profile, including reductions in triglycerides and increases in HDL. GLP-1 and amylin agonists have both been associated with lipid improvements in clinical trials. A complete lipid panel establishes the metabolic cardiovascular risk context and provides a baseline for tracking changes.
• Body composition markers: BMI, waist circumference, and where available, DEXA-derived fat and lean mass data are the primary efficacy endpoints in obesity trials. Understanding body composition biomarkers provides clinical context that weight alone does not. Lean mass preservation during weight loss is an active area of investigation for amylin-class compounds; a 2025 review by Ryan in Reviews in Endocrine and Metabolic Disorders examined whether new obesity drugs adequately preserve muscle mass during weight reduction, a question directly relevant to the amylin class.
• Comprehensive metabolic panel (CMP): Liver enzymes, kidney function markers (creatinine, BUN), and electrolytes provide baseline safety context. Amylin and GLP-1 agonists both affect gastric motility and renal physiology, and baseline organ function informs how safely any investigational compound in this class could be evaluated.

When to Take This Seriously

If your primary interest is weight management or metabolic health, there are established clinical pathways worth considering before turning to investigational compounds. Semaglutide and tirzepatide are FDA-approved, have extensive Phase 3 trial data, and are available through licensed prescribers. Understanding your current metabolic status through bloodwork — specifically fasting glucose, HbA1c, fasting insulin, and lipid markers — gives both you and a provider the objective baseline needed to evaluate candidacy for any intervention. The biomarkers relevant to metabolic health and weight management provide a starting point for that assessment.

That commitment to objective data before clinical decisions is at the core of what Superpower does: the belief, reflected in our approach to preventive health, that understanding your biology is the foundation for every health decision, whether you are evaluating FDA-approved therapies or following the emerging science in the amylin pipeline.

IMPORTANT SAFETY INFORMATION

Eloralintide (LY3841136) and amycretin are investigational compounds that are not FDA-approved for any indication as of April 2026. Neither compound is legally marketed for human use in the United States. Superpower Health does not prescribe, sell, compound, or facilitate access to either compound. This page is for educational and informational purposes only and does not constitute medical advice.

Research stage: Eloralintide has completed Phase 2 (48-week multicenter RCT); amycretin has completed Phase 1 (oral and subcutaneous) and Phase 1b/2a (subcutaneous). Phase 3 trials for both compounds are in active design or enrollment as of April 2026. Long-term safety data in large populations does not yet exist for either compound.

Theoretical contraindications and elevated-risk populations (based on proposed mechanisms, not confirmed Phase 3 human data): personal or family history of medullary thyroid carcinoma or MEN2 (amycretin, due to GLP-1 component); prior pancreatitis (amycretin); severe renal impairment; pregnancy or breastfeeding; known hypocalcemia or bone metabolism disorders; competitive athletes subject to WADA/USADA rules (both compounds are classified S0 non-approved substances on the 2026 WADA Prohibited List).

Warnings from published Phase 1/2 data: gastrointestinal adverse events (nausea, vomiting, constipation, diarrhea) are the most commonly reported adverse effects for both compounds in published studies. These are consistent with the class pharmacology of appetite-suppressing compounds and GLP-1 receptor agonism. Other adverse events and long-term organ effects are not fully characterized as of April 2026.

Products labeled as eloralintide or amycretin sold through online research compound vendors are not FDA-regulated and carry unknown contamination, dosing, and safety risks. There is no legal pathway to obtain pharmaceutical-grade eloralintide or amycretin for human use outside of an enrolled, IRB-approved clinical trial.

For ongoing clinical trial information: clinicaltrials.gov. For information about Superpower's services: superpower.com/how-it-works.

Additional Questions

What is the difference between eloralintide and cagrilintide?

Both are long-acting, injectable amylin receptor agonists designed for once-weekly dosing. Cagrilintide (Novo Nordisk) is further advanced in development, with Phase 3 REDEFINE data published in 2025. Eloralintide (Eli Lilly) is a distinct compound developed through a separate research program, with Phase 2 data published in 2025. Cagrilintide has been studied in combination with semaglutide in the CagriSema program; eloralintide's combination potential with GLP-1 agonists is a subject of ongoing investigation. This comparison is for scientific context only.

Are amylin class peptides legal in the United States?

Neither eloralintide nor amycretin is legally marketed for human use in the United States as of April 2026. Both are investigational compounds available only within registered clinical trials. Products sold under these names through research compound vendors are not FDA-regulated, not of verified pharmaceutical grade, and not legal for human use outside of approved clinical trial protocols.

Can a doctor prescribe eloralintide or amycretin?

No. Neither compound has completed the FDA approval process or received NDA approval. They are not available as prescription medications in the United States. Providers cannot prescribe investigational compounds outside of clinical trial protocols. The only legal route to access either compound in the US is enrollment in an active, registered clinical trial.

What biomarkers should I monitor if I am interested in metabolic health?

Fasting glucose, HbA1c, fasting insulin, a lipid panel (including triglycerides and ApoB), and high-sensitivity CRP are the core markers for assessing metabolic health and cardiovascular risk. These are the same markers used as primary and secondary endpoints in obesity and diabetes trials, including those studying amylin-class compounds. See the biomarkers for blood sugar stability and insulin sensitivity for additional context on interpreting these values.